********** downramps Resapp, page-156

Well I'm surprised, they have responded.......

G’day Frank,
Thanks for the email.
I can tell you’re a believer in ResApp, and i hope that it goes well.
That said, I don’t think your criticisms take Claude’s article in context.
For example, the reference to acne et al was in the context of chronic disease, not that ResApp could/should be used for such a condition.
And Claude’s commentary wasn’t suggesting that the company couldn’t be successful, but that, in his opinion, the shares are over hyped, relative to its lifecycle stage — that is, without revenues or profits.
I have no view on whether ResApp really is going to be hugely successful, or a great idea whose time may never come, but I think you’d agree that no investor should get carried away with early-stage companies — and that, if nothing else — was Claude’s point.
Thanks for taking the time to get in touch.
Fool on!